Scientific Poster , Human ADME , First-in-Human , Clinical Pharmacology

DMDG 2016 Poster: A Phase I, open-label, 2-Part study to establish absolute bioavailability

26 October 2017
Overview

Download a copy of our poster titled, 'A Phase I, open-label, 2-Part study to establish absolute bioavailability'. A Phase I, open-label, 2-Part study to establish absolute bioavailability and the ADME of evogliptin in healthy male subjects by light-label approach.

Download
Download Now
Date
26 October 2017

Your challenges. Our solutions.

Learn more about our expertise in human ADME studies.

Quotient Sciences Logo
Human ADME, Regulatory

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

By: Dr. Adam Robinson-Miller Read More
Get in touch
Humanity can't afford to wait, so neither can we.